Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
View: Text | PDF
Research Article Neuroscience

CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice

  • Text
  • PDF
Abstract

Brain arteriovenous malformations (bAVMs) are anomalies forming vascular tangles connecting the arteries and veins, which cause hemorrhagic stroke in young adults. Current surgical approaches are highly invasive, and alternative therapeutic methods are warranted. Recent genetic studies identified KRAS mutations in endothelial cells of bAVMs; however, the underlying process leading to malformation in the postnatal stage remains unknown. Here we established a mouse model of bAVM developing during the early postnatal stage. Among 4 methods tested, mutant KRAS specifically introduced in brain endothelial cells by brain endothelial cell–directed adeno-associated virus (AAV) and endothelial cell–specific Cdh5-CreERT2 mice successfully induced bAVMs in the postnatal period. Mutant KRAS led to the development of multiple vascular tangles and hemorrhage in the brain with increased MAPK/ERK signaling and growth in endothelial cells. Three-dimensional analyses in cleared tissue revealed dilated vascular networks connecting arteries and veins, similar to human bAVMs. Single-cell RNA-Seq revealed dysregulated gene expressions in endothelial cells and multiple cell types involved in the pathological process. Finally, we employed CRISPR/CasRx to knock down mutant KRAS expression, which efficiently suppressed bAVM development. The present model reveals pathological processes that lead to postnatal bAVMs and demonstrates the efficacy of therapeutic strategies with CRISPR/CasRx.

Authors

Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno

×

Figure 2

Vascular malformations in KRASG12D-induced Cdh5-CreERT2;lsl-tdTomato mice.

Options: View larger image (or click on image) Download as PowerPoint
Vascular malformations in KRASG12D-induced Cdh5-CreERT2;lsl-tdTomato mic...
(A) Survival curves of Cdh5-CreERT2;lsl-tdTomato mice injected with different amounts of AAV-CAG-DIO-KRASG12D (1 × 109, 5 × 108, 1 × 108, 5 × 107, 3 × 107, and 1 × 107 GC). (B–D) Representative images of the brain (B), spinal cord (C), and organs (D) (1 × 109 GC, P21). (E–H) Brain section images at days 5, 10, and 15 after AAV-PHP.V1-CAG-DIO-HA-KRASG12D (E–G) or control AAV-PHP.V1-CAG-DIO-MCS injection (H) in Cdh5-CreERT2;lsl-tdTomato mice (1 × 109 GC; 3 to 4 images were combined in each panel). Arrowheads indicate vascular tangles. Dotted areas are magnified in the neighboring panels. (I) The size of lesions (1 × 109 GC, total 380 vascular tangles, n = 3 brains, mean ± SD). N.D., not detected, in control AAV (MCS). (J) Inner vessel diameter in control AAV and of the lesions in KRAS-induced group. ****P < 0.0001. n = 357 and 862 vessels in 2 animals; data are shown as mean ± SD. Mann-Whitney U test was used. (K) The ratio of lesion numbers in brain regions (n = 3 brains). (L–N) HA and RASG12D expressions in the vascular tangles (P16 and P21). Scale bars: 2 mm (B), 1 mm (C), 5 mm (D), 500 μm (E–H), 100 μm (L–N, insets in F, G).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts